MetaCap

NovaBridge Biosciences (NBP) vs PDS Biotechnology (PDSB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PDS Biotechnology (PDSB) has outperformed NovaBridge Biosciences (NBP) over the past year, gaining 3.0% versus a loss of 80.4%. Over five years, PDSB leads with a -92.5% price change compared with -98.7% for NBP. NovaBridge Biosciences is the larger company by market cap ($96.3 million vs $95.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NBP-80.38%PDSB+2.97%
+122%+15%-91%
Nov 21, 20251 yearNov 20, 2026
NBP-98.79%PDSB-92.26%
+38%-34%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NBP versus PDSB key metrics
MetricNBPPDSB
Share price$0.83$0.7774
Market cap$96.28M$95.39M
1-day change-5.66%-3.70%
YTD return-79.15%+0.96%
1-year return-80.38%+2.97%
5-year return-98.69%-92.46%
EPS (TTM)$-0.69$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-46.27M$-34.50M
52-week high$5.19$1.79
52-week low$0.751$0.195
Distance from 52-week high-84.01%-56.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+944.58%+478.85%
Average volume515.66K25.64M
Shares outstanding116.00M122.70M
Employees3021
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PDSB has outperformed NBP by 83.3 percentage points over the past year.

About NovaBridge Biosciences

NBP stock →

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.

Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees

About PDS Biotechnology

PDSB stock →

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

NBP vs PDSB FAQ

Which is bigger, NovaBridge Biosciences or PDS Biotechnology?

NovaBridge Biosciences (NBP) is larger, with a market capitalization of $96.28M compared with $95.39M for PDS Biotechnology (PDSB).

Which stock has performed better over the past year, NBP or PDSB?

PDSB returned +2.97% over the past 12 months, compared with -80.38% for NBP (price return, excluding dividends). Past performance does not predict future results.

Are NovaBridge Biosciences and PDS Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons